CohBar appoints director
Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally
Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage
Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share
Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet
CohBar Inc. appointed John Amatruda to the board.
Amatruda is a co-founder and scientific adviser to the company. He is also currently on the board of CureDM, Prosciento, and Fractyl.
CohBar is a biotechnology company focused on the research and development of mitochondria-based therapeutics for age-related diseases.
